OBJECTIVE: To estimate the effectiveness of resistance assessments based on viral sequencing (genotypic antiretroviral resistance testing, GART), phenotypic antiretroviral resistance testing (PART) or virtual PART (vPART) in the management of treatment-experienced HIV-1-infected patients. DESIGN: Meta-analysis of randomized controlled trials comparing treatments aided by GART, PART and vPART, and controls. METHODS: The meta-analysis synthesized data on the proportion of patients with undetectable plasma viral load, the decrease in viral load, and the increase in CD4 cell count at 3 and 6 months after randomization. RESULTS: Ten trials were analyzed (total 2258 participants). Compared with controls, at 3 and 6 months GART increased the proportion of patients with viral load below detection by 11% [95% confidence interval (CI), 6-16], and 10% (95% CI, 5-16), respectively. The difference in viral load change was 0.27 log10 copies/ml (95% CI, 0.11-0.43) and 0.21 log10 copies/ml (95% CI, 0.09-0.34), respectively. However, no improvement was observed in the CD4 cell count at either time point: the difference in CD4 cell count -5.7 x 10(6) cells/l (95% CI, -18.8 to 7.3) and 1.2 x 10(6) cells/l (95% CI, -15.0 to 17.4), respectively, at 3 and 6 months. For PART, there was no clear evidence for any benefit versus no testing (three trials). vPART conferred a small benefit in indirect comparisons versus no testing. CONCLUSION: Evidence for benefit of antiretroviral resistance testing is sparse and limited to small short-term improvements of virologic response, mostly with GART and less with vPART. Current guidelines widely recommending the use of antiretroviral resistance testing in clinical practice are not commensurate with the available evidence.
OBJECTIVE: To estimate the effectiveness of resistance assessments based on viral sequencing (genotypic antiretroviral resistance testing, GART), phenotypic antiretroviral resistance testing (PART) or virtual PART (vPART) in the management of treatment-experienced HIV-1-infectedpatients. DESIGN: Meta-analysis of randomized controlled trials comparing treatments aided by GART, PART and vPART, and controls. METHODS: The meta-analysis synthesized data on the proportion of patients with undetectable plasma viral load, the decrease in viral load, and the increase in CD4 cell count at 3 and 6 months after randomization. RESULTS: Ten trials were analyzed (total 2258 participants). Compared with controls, at 3 and 6 months GART increased the proportion of patients with viral load below detection by 11% [95% confidence interval (CI), 6-16], and 10% (95% CI, 5-16), respectively. The difference in viral load change was 0.27 log10 copies/ml (95% CI, 0.11-0.43) and 0.21 log10 copies/ml (95% CI, 0.09-0.34), respectively. However, no improvement was observed in the CD4 cell count at either time point: the difference in CD4 cell count -5.7 x 10(6) cells/l (95% CI, -18.8 to 7.3) and 1.2 x 10(6) cells/l (95% CI, -15.0 to 17.4), respectively, at 3 and 6 months. For PART, there was no clear evidence for any benefit versus no testing (three trials). vPART conferred a small benefit in indirect comparisons versus no testing. CONCLUSION: Evidence for benefit of antiretroviral resistance testing is sparse and limited to small short-term improvements of virologic response, mostly with GART and less with vPART. Current guidelines widely recommending the use of antiretroviral resistance testing in clinical practice are not commensurate with the available evidence.
Authors: P Panagopoulos; D Paraskevis; A Antoniadou; A Papadopoulos; G Poulakou; A Hatzakis; H Giamarellou Journal: Ir J Med Sci Date: 2008-09-10 Impact factor: 1.568
Authors: Y Yazdanpanah; M Vray; J Meynard; E Losina; M C Weinstein; L Morand-Joubert; S J Goldie; H E Hsu; R P Walensky; C Dalban; P E Sax; P M Girard; K A Freedberg Journal: HIV Med Date: 2007-10 Impact factor: 3.180
Authors: Kate Buchacz; Rose Baker; Douglas J Ward; Frank J Palella; Joan S Chmiel; Benjamin Young; Bienvenido G Yangco; Richard M Novak; John T Brooks Journal: AIDS Res Treat Date: 2012-03-14
Authors: Nicholas I Paton; Cissy Kityo; Jennifer Thompson; Immaculate Nankya; Leonard Bagenda; Anne Hoppe; James Hakim; Andrew Kambugu; Joep J van Oosterhout; Mary Kiconco; Silvia Bertagnolio; Philippa J Easterbrook; Peter Mugyenyi; A Sarah Walker Journal: Lancet HIV Date: 2017-05-08 Impact factor: 12.767